[February 02, 2016] |
|
Acinetobacter Infections Pipeline Review, H2 2015 - Research and Markets
Research and Markets (http://www.researchandmarkets.com/research/rtnqws/acinetobacter)
has announced the addition of the "Acinetobacter
Infections - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic
development for Acinetobacter Infections, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Acinetobacter Infections and special features on late-stage and
discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
-
Introducion
-
Acinetobacter Infections Overview
-
Therapeutics Development
-
Pipeline Products for Acinetobacter Infections - Overview
-
Pipeline Products for Acinetobacter Infections - Comparative Analysis
-
Acinetobacter Infections - Therapeutics under Development by Companies
-
Acinetobacter Infections - Therapeutics under Investigation by
Universities/Institutes
-
Acinetobacter Infections - Pipeline Products Glance
-
Late Stage Products
-
Clinical Stage Products
-
Early Stage Products
-
Acinetobacter Infections - Products under Development by Companies
-
Acinetobacter Infections - Products under Investigation by
Universities/Institutes
-
Acinetobacter Infections - Companies Involved in Therapeutics
Development
-
Achaogen Inc.
-
Adenium Biotech ApS
-
AmpliPhi Biosciences Corporation
-
Aridis Pharmaceuticals LLC
-
AstraZeneca Plc
-
AvidBiotics Corp.
-
Emergent BioSolutions Inc.
-
Evaxion Biotech
-
F. Hoffmann-La Roche Ltd.
-
FAB Pharma
-
FOB Synthesis, Inc.
-
LegoChem Biosciences, Inc
-
Melinta Therapeutics, Inc
-
Microbiotix, Inc.
-
MicuRx Pharmaceuticals, Inc.
-
Nosopharm SAS (News - Alert)
-
Novan, Inc.
-
Omnia Molecular Ltd.
-
Pfizer Inc.
-
Phylogica Limited
-
Sarepta Therapeutics, Inc.
-
Sealife PHARMA GMBH
-
Shionogi & Co., Ltd.
-
Synthetic Biologics, Inc.
-
Techulon, Inc.
-
Tetraphase Pharmaceuticals Inc.
-
Trana Discovery, Inc.
-
Vaxdyn, S.L.
For more information visit http://www.researchandmarkets.com/research/rtnqws/acinetobacter
View source version on businesswire.com: http://www.businesswire.com/news/home/20160202005921/en/
[ Back To TMCnet.com's Homepage ]
|